I don’t think you need that footnoted caveat, simply because there isn’t $150M/year worth of room for more funding in all of AMF, Malaria Consortium’s SMC program, HKI’s vitamin A supplementation program, and New Incentives’ cash incentives for routine vaccination program all combined; these comprise the full list of GiveWell’s top charities.
Another point is that the benefits of eradication keep adding up long after you’ve stopped paying for the costs, because the counterfactual that people keep suffering and dying of the disease is no longer happening. That’s how smallpox eradication’s cost-effectiveness can plausibly be less than a dollar per DALY averted so far and dropping (Guesstimate model, analysis). Quoting that analysis:
3.10.) For how many years should you consider benefits?
It is not clear for how long we should continue to consider benefits, since the benefits of vaccines would potentially continue indefinitely for hundreds of years. Perhaps these benefits would eventually be offset by some other future technology, and we could try to model that. Or perhaps we should consider a discount rate into the future, though we don’t find that idea appealing.
Instead, we decided to cap at an arbitrary fixed amount of years set to 20 by default, though adjustable as a variable in our spreadsheet model (or by copying and modifying our Guesstimate models). We picked 20 because it felt like a significant enough amount of time for technology and other dynamics to shift.
It’s important to think through what cap makes the most sense, though, as it can have a large effect on the final model, as seen in this table where we explore the ramifications of smallpox eradication with different benefit thresholds:
I don’t think you need that footnoted caveat, simply because there isn’t $150M/year worth of room for more funding in all of AMF, Malaria Consortium’s SMC program, HKI’s vitamin A supplementation program, and New Incentives’ cash incentives for routine vaccination program all combined; these comprise the full list of GiveWell’s top charities.
Another point is that the benefits of eradication keep adding up long after you’ve stopped paying for the costs, because the counterfactual that people keep suffering and dying of the disease is no longer happening. That’s how smallpox eradication’s cost-effectiveness can plausibly be less than a dollar per DALY averted so far and dropping (Guesstimate model, analysis). Quoting that analysis: